| abstract |
The invention relates to a combination of erythropoietin glycoisoforms, in which said glycoisoforms can comprise between 4 and 10 sialic acid molecules per molecule of erythropoietin. The aforementioned combination of glycoisoforms can be used for the treatment or prevention of septicemia/sepsis. The invention also relates to a pharmaceutical composition comprising the above-mentioned combination, a cell line that produces a combination of erythropoietin glycoisoforms, methods of obtaining the cell line, a method of producing the combination of glycoisoforms and methods for the treatment and prevention of septicemia/sepsis. |